15 citations
,
May 2023 in “Aesthetic Surgery Journal” Researchers should follow the FACE-Q User's Guide for accurate results.
January 2023 in “Figshare” Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Disease-specific tools better assess quality of life in alopecia areata patients.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
95 citations
,
July 2016 in “Journal of The American Academy of Dermatology” People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
May 2025 in “Journal of Nanobiotechnology” The gel improves hair regrowth and reduces irritation in alopecia areata treatment.
2 citations
,
September 2024 in “International Journal of Dermatology” Children with alopecia areata and their caregivers experience significant emotional and quality of life challenges.
Higher air pollution increases the risk of alopecia areata.
2 citations
,
May 2021 in “Journal of pharmaceutical and biomedical analysis” A new method was developed to accurately detect and measure 47 different drug ingredients in various products.
April 2024 in “Journal of asthma and allergy” Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.
October 2022 in “Hair Transplantation” Quality control and assurance are crucial for improving hair transplant surgery outcomes.
August 2025 in “Journal of IMAB - Annual Proceeding (Scientific Papers)” The A-T advancement flap is a safe and effective method for scalp reconstruction after basal cell carcinoma removal.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Hair loss significantly affects emotional and social well-being.
July 2016 in “Hair transplant forum international” The document's content cannot be summarized because it is not accessible or understandable.
September 2019 in “Journal of Investigative Dermatology” Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
July 2025 in “Dermatology and Therapy” Patients with fewer past treatments for alopecia areata respond better to baricitinib.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
11 citations
,
January 2021 in “British Journal of Dermatology” Mutations in the AP1B1 gene cause a new syndrome with skin, hearing, and developmental issues.
1 citations
,
January 2023 Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.
2 citations
,
January 2023 in “Skin Appendage Disorders” Beard alopecia areata causes patchy beard hair loss, often treatable with janus kinase inhibitors.
January 2009 in “ScholarlyCommons (University of Pennsylvania)” The P133R mutation in AKR1D1 enzyme causes harmful bile acid buildup, explaining related health issues.
35 citations
,
June 2011 in “British Journal of Dermatology” The DQB1*03 allele is linked to higher alopecia areata risk in Italians.
6 citations
,
October 2016 in “Pediatric Dermatology” A 6-year-old girl had a rare allergic reaction to a hair regrowth treatment.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
November 2025 in “Frontiers in Immunology” SQSTM1 gene issues may increase the risk of alopecia areata.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.